Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02628990
Other study ID # YD2005
Secondary ID
Status Completed
Phase N/A
First received December 1, 2015
Last updated December 9, 2015
Start date June 2005
Est. completion date November 2005

Study information

Verified date December 2015
Source Raisio Group
Contact n/a
Is FDA regulated No
Health authority Finland: Ethics Committee
Study type Interventional

Clinical Trial Summary

The aim is to investigate the effects of yoghurt drinks containing two doses of plant stanol ester either with or without added camelina oil on the serum cholesterol levels in moderately hypercholesterolemic subjects


Recruitment information / eligibility

Status Completed
Enrollment 155
Est. completion date November 2005
Est. primary completion date August 2005
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria:

- BMI < 30 kg/m2

- moderate hypercholesterolemia (fasting total cholesterol between 5-8 mmol/l)

- serum triglycerides < 3 mmol/l.

- normal liver, kidney and thyroid function

- subjects must voluntarily sign the informed consent

Exclusion Criteria:

- use of cholesterol lowering foods or dietary supplements within 21 days before the start of the intervention

- lipid lowering medication

- history of unstable coronary artery disease (myocardial infarction, coronary artery bypass craft (CABG), percutaneous transluminal coronary angioplasty (PTCA) within the previous 6 months, diabetes, hyperglycemia, temporal ischemic attack and malignant diseases

- pregnancy or lactation

- alcohol abuse

- subjects with intolerance to any ingredient of the test products

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
1.6 g plant stanols
Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
2 g plant stanols
Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
1.6 g plant stanols and camelina oil
Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
2 g plant stanols and camelina oil
Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
Placebo
Lipid-lowering effect of Placebo Yoghurt Drink

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Raisio Group University of Turku

Outcome

Type Measure Description Time frame Safety issue
Primary Percentual change in serum LDL-cholesterol Percentual change [end of intervention - start of intervention] in serum LDL-cholesterol between experimental and placebo groups 4 weeks No
Primary Absolute change in serum LDL-cholesterol Absolute change [end of intervention - start of intervention] in serum LDL-cholesterol between experimental and placebo groups, mmol/l 4 weeks No
Secondary Percentual change in serum total cholesterol Percentual change [end of intervention - start of intervention] in serum total cholesterol between experimental and placebo groups 4 weeks No
Secondary Absolute change in serum total cholesterol Absolute change [end of intervention - start of intervention] in serum total cholesterol between experimental and placebo groups, mmol/l 4 weeks No
Secondary Percentual change in serum non-HDL cholesterol Percentual change [end of intervention - start of intervention] in serum nonHDL cholesterol between experimental and placebo groups 4 weeks No
Secondary Absolute change in serum non-HDL cholesterol Absolute change [end of intervention - start of intervention] in serum nonHDL cholesterol between experimental and placebo groups, mmol/l 4 weeks No
Secondary Percentual change in serum triglycerides Percentual change [end of intervention - start of intervention] in serum triglycerides between experimental and placebo groups 4 weeks No
Secondary Absolute change in serum triglycerides Absolute change [end of intervention - start of intervention] in serum triglycerides between experimental and placebo groups, mmol/l 4 weeks No
See also
  Status Clinical Trial Phase
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Recruiting NCT03947866 - Ezetimibe-Rosuvastatin Evaluation Study
Completed NCT01709513 - Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) Phase 3
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed NCT02550288 - A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383) Phase 3
Completed NCT03929198 - Translation of Pritikin Program to the Community N/A
Completed NCT04485793 - Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia N/A
Completed NCT02341924 - Validating the "Foods for Health" Portfolio of Functional Food Products N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Completed NCT01941836 - Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients Phase 2
Completed NCT01934608 - The Effect of Synching Prescription Refills on Adherence N/A
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01678521 - Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients N/A
Completed NCT01670734 - Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects Phase 1
Completed NCT01370590 - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1) Phase 3
Completed NCT01370603 - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1) Phase 3
Completed NCT01446679 - Special Drug Use-Results Survey of Lipitor Tablets N/A
Completed NCT01768403 - Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia N/A
Completed NCT01478789 - Efficacy of Plant Sterol-Fortified Dairy Product on Plasma Lipid and Plant Sterol Concentrations in Humans N/A